Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race

Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline. The deal comes one month after Merck agreed to pay $2.8 billion to acquire VelosBio for its anti-ROR1 ADC.